Susquehanna International Group, LLP Taysha Gene Therapies, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 142,463 shares of TSHA stock, worth $216,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142,463
Previous 176,492
19.28%
Holding current value
$216,543
Previous $354,000
30.51%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TSHA
# of Institutions
126Shares Held
150MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$30.4 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$26.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$17.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$16.5 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$15.9 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $73.5M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...